Get your TAVR Info Kit
We’d like to send you a kit packed with valuable information and resources to help you better understand TAVR.
Get yours today
YOU CAN’T FIX A FAILING VALVE ON YOUR OWN1-4
Severe aortic stenosis, also known as heart valve failure, is not only scary, it's dangerous—so it's good to know you have a treatment like TAVR (transcatheter aortic valve replacement). TAVR is a way to fix your failing valve without open heart surgery.
Diet and exercise may help fix conditions like high cholesterol and high blood pressure, but not symptoms of heart valve failure. It only gets worse over time and may become deadly without treatment. You have options. Ask your doctor if TAVR is one of them.
ALL ABOUT TAVR
Who
All patients diagnosed with heart valve failure and who are experiencing symptoms should ask for a TAVR evaluation. TAVR may also be appropriate for symptomatic patients with bicuspid aortic valves, and for those at high risk for surgery and who need another valve procedure (valve-in-valve).2,5
What
TAVR doesn't involve opening the chest, meaning it's a minimally invasive way to replace a failing aortic heart valve.*6,7
When
As soon as you’re diagnosed with heart valve failure, it’s time to get referred.8
Where
Ask your doctor to refer you to a TAVR Hospital, where you will be evaluated by a Heart Valve Team to see if TAVR is right for you.
Why
Your life belongs to you, not heart valve failure. Take it back with TAVR.
Dr. Dearman, a TAVR patient and cardiac surgeon
What happens when a cardiac surgeon is the one who needs a TAVR?
Watch video
Most TAVR patients:9-13
Are finished with
the procedure in
about 1 hour
Are up and
walking within
hours
Go home the
next day
Recover quickly and
start feeling like
themselves in
about 30 days
The major risks of TAVR include death, stroke, serious damage to the arteries, or
SAPIEN 3 TAVR is proven superior to surgery in low-risk patients at 1 year—and proven equally effective at 5 years.*6,13
*
The PARTNER 3 Trial, SAPIEN 3 TAVR proven superior to surgery on the primary endpoint of all-cause death, all stroke, and re-hospitalization (valve-related or procedure-related and including heart failure) at one year, and multiple pre-specified secondary endpoints in low risk patients.
PARTNER 3 Trial 5-Year Results in low-risk patients – Low rates of cardiovascular mortality through five years (5.5% SAPIEN 3 TAVR to 5.1% SAVR). Low rates of all-cause mortality through five years (10.1% SAPIEN 3 TAVR vs. 8.2% with SAVR). Low rates of disabling stroke through five years (2.9% SAPIEN 3 TAVR to 2.7% SAVR). Low rates of stroke through five years (5.8% SAPIEN 3 TAVR vs. 6.4% SAVR). Lower rates of rehospitalization with SAPIEN 3 TAVR through five years (13.7% vs. 17.4%).
Have heart valve failure?
It’s critical to get referred to a Heart Valve Team
Start your Informed Decision Guide
This 7-minute questionnaire can help you and your doctor decide the best treatment path for you.
Begin here
References:
1.Shipton B, Wahba H. Valvular heart disease: review and update. Am Fam Physician. 2001;63(11):2201-2208.
2.Otto CM, Nishimura RA, Bonow RO, et al. 2020 ACC/AHA guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2021;143(5):e72-e227.
3.Barone Gibbs B, Hivert MF, Jerome GJ, et al. Physical activity as a critical component of first-line treatment for elevated blood pressure or cholesterol: who, what, and how?: A Scientific statement from the American Heart Association. Hypertension. 2021;78(2):e26-e37.
4.Malaisrie SC, McDonald E, Kruse J, et al. Mortality while waiting for aortic valve replacement. Ann Thorac Surg. 2014;98(5):1564-1571.
5.Landes U, Webb JG, De Backer O, et al. Repeat transcatheter aortic valve replacement for transcatheter prosthesis dysfunction. J Am Coll Cardiol. 2020;75(16):1882-1893.
6.Mack MJ, Leon MB, Thourani VH, et al. Transcatheter aortic-valve replacement in low-risk patients at five years. N Engl J Med. 2023;389(21):1949-1960.
7.Webb JG, Dvir D. Transcatheter aortic valve replacement for bioprosthetic aortic valve failure: the valve-in-valve procedure. Circulation. 2013;127(25):2542-2550.
8.Otto CM. Timing of aortic valve surgery. Heart. 2000;84(2):211-218.
9.Mack MJ, Leon MB, Thourani VH, et al. Transcatheter aortic-valve replacement with a balloon-expandable valve in low-risk patients [supplementary appendix]. N Engl J Med. 2019;380(18):1695-1705.
10.Rheude T, Pellegrini C, Landt M, et al. Multicenter comparison of transcatheter aortic valve implantation with the self-expanding ACURATE neo2 versus Evolut PRO transcatheter heart valves. Clin Res Cardiol. 2024;113(1):38-47.
11.Grubb KJ, Gada H, Mittal S, et al. Clinical impact of standardized TAVR technique and care pathway: insights from the Optimize PRO study. JACC Cardiovasc Interv. 2023;16(5):558-570.
12.Wood DA, Lauck SB, Cairns JA, et al. The Vancouver 3M (Multidisciplinary, Multimodality, But Minimalist) Clinical Pathway facilitates safe next-day discharge home at low-, medium-, and high-volume transfemoral transcatheter aortic valve replacement centers: the 3M TAVR Study. JACC Cardiovasc Interv. 2019;12(5):459-469.
13.Mack MJ, Leon MB, Thourani VH, et al. Transcatheter aortic-valve replacement with a balloon-expandable valve in low-risk patients. N Engl J Med. 2019;380(18):1695-1705.
Patients and/or clinicians quoted on this website have received compensation from Edwards Lifesciences.